<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03852446</url>
  </required_header>
  <id_info>
    <org_study_id>NLG2111</org_study_id>
    <nct_id>NCT03852446</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers</brief_title>
  <acronym>NLG2111</acronym>
  <official_title>A Phase 1, Randomized Trial to Evaluate the Pharmacokinetics and Safety of Single Ascending Doses of Indoximod HCl (F2) Tablets (Part 1) and to Compare the Oral Bioavailability of Indoximod Cl (F2) Tablets and Indoximod Free Base Capsule Formulations and the Effect of Food (Part 2) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NewLink Genetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lumos Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 2-part study will assess the effect of formulation and food on the pharmacokinetics of
      Indoximod in healthy volunteers. Part 1 is a randomized single ascending dose study of
      indoximod salt formulation to characterize the PK profile and determine the safety and
      tolerability of each dose in healthy male volunteers. Part 2 is an open-label, randomized,
      3-period, 3-way crossover study. Participants will receive single doses of Indoximod base or
      salt formulation, in the fasted or fed state.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 5, 2018</start_date>
  <completion_date type="Actual">August 14, 2018</completion_date>
  <primary_completion_date type="Actual">March 5, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve</measure>
    <time_frame>up to 20 Days</time_frame>
    <description>Part 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Serum concentrations (Cmax/Steady State)</measure>
    <time_frame>up to 20 Days</time_frame>
    <description>Part 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Serum concentrations (Cmax/Steady State)</measure>
    <time_frame>up to 4 Days</time_frame>
    <description>Part 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with adverse events</measure>
    <time_frame>up to 18 Days</time_frame>
    <description>Part 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with adverse events</measure>
    <time_frame>up to 36 Days</time_frame>
    <description>Part 2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: Single Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Bioavailability and Food Effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of Indoximod HCL (F2) formulation under fasting conditions
Single dose of Indoximod HCL (F2) formulation under fed conditions
Single dose of Indoximod base formulation under fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indoximod HCL (F2) tablets</intervention_name>
    <description>The doses will be ascending per cohort from 600 mg to 2400 mg</description>
    <arm_group_label>Part 1: Single Ascending Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indoximod base formulation</intervention_name>
    <description>Single oral administration of 1200 mg</description>
    <arm_group_label>Part 2: Bioavailability and Food Effect</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The matching placebo doses will be ascending per cohort from 1 to 4 tablets</description>
    <arm_group_label>Part 1: Single Ascending Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indoximod HCL (F2) tablets</intervention_name>
    <description>Single oral administration of 1200 mg</description>
    <arm_group_label>Part 2: Bioavailability and Food Effect</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smoker for at least 3 months

          -  BMI within 18 to 30 kg/m2

          -  Able to speak, read, and understand English or Spanish

        Exclusion Criteria:

          -  Clinically significant cardiac, pulmonary, hepatic or renal disease

          -  History of substance abuse or alcohol dependence within past 2 years

          -  Inability to fast for a minimum of 14 hours

          -  Inability to swallow large capsules/tablets

          -  Pending legal charges or is on probation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene Kennedy, MD</last_name>
    <role>Study Director</role>
    <affiliation>NewLink Genetics Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Frontage Clinical Services, Inc.</name>
      <address>
        <city>Secaucus</city>
        <state>New Jersey</state>
        <zip>07407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2019</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Indoximod</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tryptophan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

